The start-up known as Mindstrong Health is one company that is focused on Neurological treatments. Mindstrong Health yesterday stated that they managed to get 14 million dollars in the initial round of financing. This was done with the intention of its neuropsychiatric treatment as well as its platform for diagnosis of such conditions. The company has come up with a platform which is Al-powered, and it is intended to observe interaction patterns via smartphones to monitor brain function. The platform looks to give biomarkers of cognition and biomarkers that are digital and uninterrupted. Dr. Tom Insel, who is the President and co-founder of Mindstrong Health said that he was impressed by the steps taken by the company to transform the scrolling or typing patterns of individuals while on their smartphones to a pinpoint way to measure the cognitive function. This new cutting edge approach to assess is just but a stepping stone for the foundation to invent better means of improving mental health. Check out LinkedIn to know more.
Foresite Capital led the initial round of financing alongside ARCH Venture, and they were later joined by One Mind Brain Health Impact Fund, Optum Ventures and also Berggruen Holdings, as the Calif-based company stated. Jim Tananbaum, the CEO of Foresite Capital, stated that the founding team of Mindstrong Health provides incomparable comprehension of the serious problems within the medical circles when it comes to attending to patients that have disorders related to cognitive health. The fusion of Rick, Tom and Paul’s knowledge technical vision and leadership, anyone intent on outcomes of such patients shall acquire a platform that is innovative which improves as well as greatly modernizes the provision of care to the patients.
Dr. Paul Dagum, CEO of Mindstrong Health, notes that modern medical care and treatment is dependent on measurement that is objective but despite this, mental health tracking depends on the reports coming from clinical environments. To get better results for mental disorder patients, the need to be measured objectively just like any other chronic disease.
Jim Tananbaum, who is the founding CEO at Foresite Capital Management. James has successfully led 21 healthcare companies these being the likes of Amerigroup, Jazz Pharmaceuticals, and Amira Pharmaceuticals. Before this, he founded and served as management at Theravance and also GelTex Pharmaceuticals, which got absorbed by Genzyme for 1.6 billion dollars later on.
James has a Master’s Degree attained in Harvard Med School and an additional MBA at Harvard Business School and later a BSSE and BS Yale University.